FI112169B - Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi - Google Patents
Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi Download PDFInfo
- Publication number
- FI112169B FI112169B FI940674A FI940674A FI112169B FI 112169 B FI112169 B FI 112169B FI 940674 A FI940674 A FI 940674A FI 940674 A FI940674 A FI 940674A FI 112169 B FI112169 B FI 112169B
- Authority
- FI
- Finland
- Prior art keywords
- injection
- preservative
- solution
- human protein
- process according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4126983 | 1991-08-15 | ||
DE4126983A DE4126983A1 (de) | 1991-08-15 | 1991-08-15 | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
PCT/EP1992/001822 WO1993003744A1 (de) | 1991-08-15 | 1992-08-10 | Verfahren zur herstellung von humanproteinhaltigen, konservierten arzneimitteln für infusions- oder injektionszwecke |
EP9201822 | 1992-08-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI940674A FI940674A (fi) | 1994-02-14 |
FI940674A0 FI940674A0 (fi) | 1994-02-14 |
FI112169B true FI112169B (fi) | 2003-11-14 |
Family
ID=6438353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI940674A FI112169B (fi) | 1991-08-15 | 1994-02-14 | Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi |
Country Status (25)
Country | Link |
---|---|
US (2) | US5503827A (no) |
EP (2) | EP0528313A1 (no) |
JP (1) | JP3670660B2 (no) |
KR (1) | KR100263282B1 (no) |
AT (1) | ATE145138T1 (no) |
AU (2) | AU678756B2 (no) |
CA (1) | CA2115348C (no) |
CZ (1) | CZ284853B6 (no) |
DE (2) | DE4126983A1 (no) |
DK (1) | DK0607156T3 (no) |
ES (1) | ES2094923T3 (no) |
FI (1) | FI112169B (no) |
GE (1) | GEP19981289B (no) |
GR (1) | GR3022037T3 (no) |
HU (1) | HU227421B1 (no) |
IL (1) | IL102775A (no) |
MX (1) | MX9204636A (no) |
NO (1) | NO309844B1 (no) |
RU (1) | RU2091068C1 (no) |
SG (1) | SG66226A1 (no) |
SK (1) | SK281910B6 (no) |
TW (1) | TW351677B (no) |
UA (1) | UA26343C2 (no) |
WO (1) | WO1993003744A1 (no) |
ZA (1) | ZA926122B (no) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3939346A1 (de) * | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
DE4242919A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
SE9300105D0 (sv) * | 1993-01-15 | 1993-01-15 | Kabi Pharmacia Ab | Stable protein solution |
US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
JP3541054B2 (ja) * | 1994-04-21 | 2004-07-07 | ユニ・チャーム株式会社 | 使い捨ておむつ |
US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
EP1602667B1 (en) * | 1995-06-07 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Aqueous formulation comprising TFPI and solubilizing agents |
US5888968A (en) * | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP0784982A3 (en) * | 1996-01-19 | 1999-08-18 | Eli Lilly And Company | Obesity protein formulations |
EP0784979A3 (en) * | 1996-01-19 | 1999-03-03 | Eli Lilly And Company | Obesity protein formulations |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
US6410511B2 (en) * | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
DE19716154A1 (de) * | 1997-04-18 | 1998-10-22 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren |
ES2179414T3 (es) * | 1997-11-22 | 2003-01-16 | Roche Diagnostics Gmbh | Procedimiento mejorado de estabilizacion de proteinas. |
CA2312009A1 (en) * | 1997-11-28 | 1999-06-10 | Roche Diagnostics Gmbh | An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes |
JP3723857B2 (ja) * | 1998-02-04 | 2005-12-07 | 日本ケミカルリサーチ株式会社 | ヒト成長ホルモン含有水性医薬組成物 |
KR100389726B1 (ko) * | 1998-03-06 | 2003-06-27 | 쥬가이 세이야쿠 가부시키가이샤 | 안정한 과립구 콜로니-자극 인자 함유 제제 |
US20050203187A1 (en) * | 1998-06-01 | 2005-09-15 | Verbiscar Anthony J. | Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof |
DE69928472T2 (de) | 1998-08-07 | 2006-08-10 | Curis, Inc., Cambridge | Stabilisierte pharmazeutische Zusammensetzungen von Hedgehog-Proteinen und deren Verwendung |
US6979442B1 (en) * | 1998-08-17 | 2005-12-27 | Pfizer Inc. | Stabilized protein compositions |
US6696056B1 (en) * | 1999-04-09 | 2004-02-24 | Ortho Mcneil Pharmaceutical, Inc. | Pharmaceutical compositions of erythropoietin |
HUP0202246A3 (en) * | 1999-07-22 | 2010-01-28 | Aventis Pharma Inc | Multi-dose erythropoietin formulations |
EE200200038A (et) | 1999-07-22 | 2003-04-15 | Aventis Pharmaceuticals Inc. | Konservitud farmatseutilised preparaadid |
PT1129720E (pt) | 2000-02-29 | 2004-08-31 | Pfizer Prod Inc | Factor estimulador de colonias de granulocitos estabilizado |
US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
KR20050012224A (ko) * | 2002-05-21 | 2005-01-31 | 다이이찌 산토리 파마 가부시키가이샤 | 그렐린 함유 의약 조성물 |
SI21257A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin |
WO2004084859A2 (en) * | 2003-03-21 | 2004-10-07 | Nastech Pharmaceutical Company Inc. | Nasal calcitonin formulations containing chlorobutanol |
AU2003901515A0 (en) * | 2003-04-02 | 2003-04-17 | Norika Holdings | Sterilisation process for pharmaceutical product |
CA2528988C (en) * | 2003-06-10 | 2012-05-01 | Lg Life Sciences Ltd. | Stable, aqueous solution of human erythropoietin, not containing serum albumin |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
US7851433B2 (en) * | 2003-08-13 | 2010-12-14 | Novartis Vaccines And Diagnostics, Inc. | Method of purifying TFPI and TFPI analogs |
EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
US20080193997A1 (en) * | 2004-08-24 | 2008-08-14 | Kenji Kangawa | Liquid Preparation of Physiologically Active Peptide |
EP1916997B1 (en) * | 2005-08-05 | 2018-04-18 | Amgen Inc. | Stable aqueous protein pharmaceutical formulations and their preparation |
DE202006020194U1 (de) * | 2006-03-01 | 2007-12-06 | Bioceuticals Arzneimittel Ag | G-CSF-Flüssigformulierung |
RS53404B (en) * | 2007-08-27 | 2014-10-31 | Ratiopharm Gmbh | LIQUID FORMULATION OF G-CSF CONJUGATES |
WO2009027076A1 (de) | 2007-08-27 | 2009-03-05 | Biogenerix Ag | Flüssigformulierung von g-csf |
EP2219602A1 (en) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
ES2372470T3 (es) * | 2008-02-08 | 2012-01-20 | Biogenerix Ag | Formulación líquida de fsh. |
US8120369B2 (en) | 2009-03-02 | 2012-02-21 | Harris Corporation | Dielectric characterization of bituminous froth |
AU2010299079A1 (en) | 2009-09-25 | 2012-05-17 | R-Tech Ueno, Ltd. | Eye drops |
ES2716088T3 (es) | 2010-02-04 | 2019-06-10 | Csl Behring Ag | Preparado de inmunoglobulina |
EP2361636A1 (en) | 2010-02-26 | 2011-08-31 | CSL Behring AG | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
US11905525B2 (en) * | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
CN112236130A (zh) * | 2018-04-09 | 2021-01-15 | 得克萨斯州大学系统董事会 | 使用外排体对癌基因的治疗性靶向 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3106073A1 (de) * | 1981-02-19 | 1982-08-19 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen |
GB2177914B (en) * | 1985-06-04 | 1989-10-25 | Chugai Pharmaceutical Co Ltd | A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia |
DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
ATE121629T1 (de) * | 1989-07-14 | 1995-05-15 | Praxis Biolog Inc | Stabile interleukine enthaltende impfstoffzusammensetzungen. |
DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
US5661125A (en) | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
-
1991
- 1991-08-15 DE DE4126983A patent/DE4126983A1/de not_active Withdrawn
-
1992
- 1992-08-05 TW TW081106209A patent/TW351677B/zh not_active IP Right Cessation
- 1992-08-10 SG SG1996001887A patent/SG66226A1/en unknown
- 1992-08-10 AU AU24094/92A patent/AU678756B2/en not_active Expired
- 1992-08-10 DK DK92916938.1T patent/DK0607156T3/da active
- 1992-08-10 KR KR1019940700453A patent/KR100263282B1/ko not_active IP Right Cessation
- 1992-08-10 CA CA002115348A patent/CA2115348C/en not_active Expired - Lifetime
- 1992-08-10 HU HU9400416A patent/HU227421B1/hu unknown
- 1992-08-10 CZ CZ94287A patent/CZ284853B6/cs not_active IP Right Cessation
- 1992-08-10 AT AT92916938T patent/ATE145138T1/de active
- 1992-08-10 EP EP92113571A patent/EP0528313A1/de active Pending
- 1992-08-10 SK SK148-94A patent/SK281910B6/sk not_active IP Right Cessation
- 1992-08-10 DE DE59207523T patent/DE59207523C5/de not_active Expired - Lifetime
- 1992-08-10 EP EP92916938A patent/EP0607156B1/de not_active Expired - Lifetime
- 1992-08-10 IL IL10277592A patent/IL102775A/en not_active IP Right Cessation
- 1992-08-10 UA UA94005433A patent/UA26343C2/uk unknown
- 1992-08-10 WO PCT/EP1992/001822 patent/WO1993003744A1/de active IP Right Grant
- 1992-08-10 US US08/193,002 patent/US5503827A/en not_active Expired - Lifetime
- 1992-08-10 JP JP50407293A patent/JP3670660B2/ja not_active Expired - Lifetime
- 1992-08-10 RU RU9294016163A patent/RU2091068C1/ru active
- 1992-08-10 ES ES92916938T patent/ES2094923T3/es not_active Expired - Lifetime
- 1992-08-11 MX MX9204636A patent/MX9204636A/es unknown
- 1992-08-14 ZA ZA926122A patent/ZA926122B/xx unknown
- 1992-10-15 GE GEAP19923057A patent/GEP19981289B/en unknown
-
1994
- 1994-02-14 FI FI940674A patent/FI112169B/fi not_active IP Right Cessation
- 1994-02-14 NO NO940499A patent/NO309844B1/no not_active IP Right Cessation
-
1996
- 1996-01-30 US US08/593,579 patent/US6303113B1/en not_active Expired - Fee Related
- 1996-12-13 GR GR960403464T patent/GR3022037T3/el unknown
-
1997
- 1997-03-17 AU AU16339/97A patent/AU710768B2/en not_active Expired
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI112169B (fi) | Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi | |
EP0909564B1 (en) | Erythropoietin solution preparation stabilized with amino acids | |
EP1180368B1 (en) | Freeze dried hgf preparations | |
EP2501367B1 (en) | Formulation for HGH and RHIGF-1 combination | |
JP3927248B2 (ja) | Hgf凍結乾燥製剤 | |
JP3143470B2 (ja) | ポリペプチド含有の皮下または筋肉内投与用医薬組成物 | |
JP2014208656A (ja) | 成長ホルモン製剤 | |
CA2792965A1 (en) | Stable aqueous mia/cd-rap formulations | |
CN1802171B (zh) | 不包含血清白蛋白的人红细胞生成素的稳定水溶液 | |
US7468351B2 (en) | Erythropoietin solution formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Name/ company changed in application |
Owner name: ROCHE DIAGNOSTICS GMBH |
|
MA | Patent expired |